FDA Determines Regulatory Review Period for VERAFLOX Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for VERAFLOX, a patent extension application submitted to the U.S. Patent and Trademark Office (USPTO), Department of Commerce, for an animal drug product patent.